Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Joint Stock Company "Biocad" is currently navigating 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are evenly distributed across 4 distinct examiners and a matching number of art units. ROGERS, ERIC JASON is the busiest examiner, currently managing 1 pending action.
The presence of those art units for the matters indicates a wide technical breadth in the company's current filings. Because each of the 4 pending office actions is handled by a different examiner, the prosecution strategy must be highly individualized. There is no overlap between the examiners or the units, which suggests that the matters cover distinct innovations within Biotechnology & Pharmaceuticals.
Practitioners should be prepared for different examination styles across those units. The decentralized nature of the examiners means that the applicant will receive a variety of perspectives on their patent claims. This structure requires a flexible approach to meet the specific standards of each of the units. ROGERS, ERIC JASON oversees 1 pending action, representing one of the unique paths.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 1 | 56.9% | +33.2% |
| RAVINDRA, KRISHNA NUGGEHALLI | 1 | 47.1% | +36.5% |
| VIGIL, TORIANA NICHOLE | 1 | 52.9% | +26.8% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17296629 | DNA CUTTING MEANS BASED ON CAS9 PROTEIN FROM DEFLUVIIMONAS SP. | VYAS, KEYUR ANILKUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17637113 | AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-PD1 ANTIBODY PROLGOLIMAB AND USE THEREOF | VIGIL, TORIANA NICHOLE | 50d overdue |
| 17775626 | USE OF CAS9 PROTEIN FROM THE BACTERIUM PASTEURELLA PNEUMOTROPICA | RAVINDRA, KRISHNA NUGGEHALLI | 15d |
| 18684921 | Isolated modified capsid protein VP1 from adeno-associated virus serotype 5 (AAV5), capsid and vector based thereon | ROGERS, ERIC JASON | — |
| 17296629 | DNA CUTTING MEANS BASED ON CAS9 PROTEIN FROM DEFLUVIIMONAS SP. | VYAS, KEYUR ANILKUMAR | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1636 | 1 |
| 1612 | 1 |
| 1600 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684921 | Isolated modified capsid protein VP1 from adeno-associated virus serotype 5 (AAV5), capsid and vector based thereon | ROGERS, ERIC JASON | 1638 | §112 | Non-Final OA | — | Pending | Feb 20, 2024 |
| 17775626 | USE OF CAS9 PROTEIN FROM THE BACTERIUM PASTEURELLA PNEUMOTROPICA | RAVINDRA, KRISHNA NUGGEHALLI | 1636 | §103 | Final Rejection | 15d | Pending | May 10, 2022 |
| 17637113 | AQUEOUS PHARMACEUTICAL COMPOSITION OF ANTI-PD1 ANTIBODY PROLGOLIMAB AND USE THEREOF | VIGIL, TORIANA NICHOLE | 1612 | §103 | Non-Final OA | 50d overdue | Pending | Feb 22, 2022 |
| 17296629 | DNA CUTTING MEANS BASED ON CAS9 PROTEIN FROM DEFLUVIIMONAS SP. | VYAS, KEYUR ANILKUMAR | 1600 | §103§112 | Non-Final OA | — | Pending | May 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJoint Stock Company "Biocad" has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Eric Jason Rogers has the most, with 1 of Joint Stock Company "Biocad"'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
